Indivior Pharmaceuticals, Inc.
Financials
Valuation Metrics
Indivior Pharmaceuticals, Inc.'s Market Cap is $4.42B. At end of 2025 it was $4.49B. Ranked #1492 of 3,112 in US market (top 48%), #519 of 1,445 on NASDAQ (top 36%), #83 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 31%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $4.42B | US#1,492/3,112 Sec#83/269 |
| Revenue | $1.29B | US#1,780/3,112 Sec#47/269 |
| Net Income | $251M | US#1,154/3,112 Sec#41/269 |
| Total Assets | $1.20B | US#2,368/3,112 Sec#87/269 |
| Net Assets | $117M | US#2,859/3,112 Sec#221/269 |
| Employees | 827 | US#1,288/3,112 Sec#36/269 |
| Value | ||
| P/E | 17.60x | US#857/3,112 Sec#33/269 |
| P/B | 37.75x | US#2,904/3,112 Sec#245/269 |
| PEG | 0.20x | US#307/3,112 Sec#14/269 |
| P/S | 3.42x | US#1,909/3,112 Sec#53/269 |
| EV/EBITDA | 13.50x | US#1,272/3,112 Sec#41/269 |
| FCF Yield | -4.18% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROA | 20.97% | US#83/3,112 Sec#19/269 |
| Op. Margin | 33.31% | US#350/3,112 Sec#19/269 |
| Revenue Growth | 19.17% | US#787/3,112 Sec#78/269 |
| Earnings Growth | 89.36% | US#379/3,112 Sec#13/269 |
| Financial Health | ||
| Debt Ratio | 1146.15% | US#2,812/3,112 Sec#248/269 |
| Total Debt | $509M | US#1,806/3,112 Sec#58/269 |
| FCF | $-185M | US#2,719/3,112 Sec#211/269 |
| Cash | $175M | US#1,821/3,112 Sec#128/269 |
| Current Ratio | 0.86x | US#2,420/3,112 Sec#266/269 |
| Net Debt/EBITDA | 0.95x | US#996/3,112 Sec#49/269 |
| Performance | ||
| 1Y Return | 77.53% | US#442/3,112 Sec#96/269 |
| 1M Return | -6.11% | US#2,345/3,112 Sec#133/269 |
| From 52W High | -12.71% | US#1,245/3,112 Sec#69/269 |
| 1Y MDD | -21.37% | US#796/3,112 Sec#37/269 |
| Trading | ||
| Volume | 6,647,747 shares | US#277/3,112 Sec#21/269 |
| Trading Value | $255M | US#425/3,112 Sec#20/269 |
| Per Share | ||
| EPS | $1.68 | US#1,376/3,112 Sec#47/269 |
Company Info
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.